INCB018424 (Ruxolitinib)

Name: INCB018424 (Ruxolitinib)
Brand: Adooq Bioscience
SKU: A11041
Rating: 100 (6 reviews)

Catalog No.: A11041

JAK1/2 Inhibitor

Product Citations (6)

INCB018424 (Ruxolitinib) Chemical Structure

CAS NO. 941678-49-5

INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;

Availability: In stock

Package	Price	Qty
5 mg	$60.00
10 mg	$70.00
25 mg	$90.00
100 mg	$160.00
10mM * 1mL in DMSO	$60.00
Custom Size	Get quote

Free Overnight Delivery on orders over $500

Next day delivery by 10:00 a.m. Order now.

Bulk Inquiry

Get Free Sample

Price Match

Add to Wishlist

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Adooq Products cited in reputable paper

Publications Citing Use of Adooq INCB018424 (Ruxolitinib)

Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
Daniel Doheny, .et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis, Oncogene, 2020, Oct;39(42):6589-6605 PMID: 32929154
Rasmus Siersbek, .et al. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis, Cancer cell, 2020, Jul 6;S1535-6108(20)30311-1 PMID: 32679107
Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Kagoya Y, .et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2., Blood., 2014, Nov 6;124(19):2996-3006 PMID: 25217696

Biological Activity

INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;

Solubility *

In vitro (25°C)	DMSO	59 mg/mL (192.57 mM)
	Water	Insoluble
	Ethanol	59 mg/mL (192.57 mM)
In vivo	2% DMSO+30% PEG 300+ddH2O	4 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	32.64 mL	163.19 mL	326.37 mL
0.5 mM	6.53 mL	32.64 mL	65.27 mL
1 mM	3.26 mL	16.32 mL	32.64 mL
5 mM	0.65 mL	3.26 mL	6.53 mL

*The above data is based on the productmolecular weight 306.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Chemical Properties

Catalog Num	A11041
Actions	Inhibitor
CAS No.	941678-49-5
Formula	C17H18N6
M. Wt	306.4
Purity	>98%
Synonyms	Ruxolitinib, INCB18424
SMILES	C1CCC(C1)[[email protected]@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
Storage	Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.